A5032257569- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Infectious Diseases and Tuberculosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Diagnosis and treatment of tuberculosis
- Pneumonia and Respiratory Infections
- Infectious Diseases and Mycology
- Pharmaceutical studies and practices
- Manufacturing Process and Optimization
- Advanced Manufacturing and Logistics Optimization
- Robot Manipulation and Learning
- Cystic Fibrosis Research Advances
- Antibiotics Pharmacokinetics and Efficacy
- Tracheal and airway disorders
- Flexible and Reconfigurable Manufacturing Systems
- Immunodeficiency and Autoimmune Disorders
- Viral Infections and Outbreaks Research
- Scheduling and Optimization Algorithms
- Orthopedic Infections and Treatments
- Vaccine Coverage and Hesitancy
- Digital Transformation in Industry
- Computational Drug Discovery Methods
- Pediatric health and respiratory diseases
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Actinomycetales infections and treatment
Sotiria General Hospital
2011-2024
University General Hospital Attikon
2024
G. Papanikolaou General Hospital
2024
Aristotle University of Thessaloniki
2024
Theageneio General Hospital
2021
Ministry of Health
2016-2018
University of Patras
2018
Chest Diseases Hospital
2016
Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. This study aimed evaluate the safety effectiveness of bedaquiline-containing regimens in a large, retrospective, observational conducted 25 centres 15 countries five continents.428 culture-confirmed MDR-TB cases were analysed (61.5% male; 22.1% HIV-positive, 45.6% XDR-TB). admitted hospital for median (interquartile range (IQR)) 179 (92-280) days exposed 168...
The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) management of adverse events.The aim this prospective study was to evaluate the frequency severity events anti-tuberculosis (TB) drugs in a cohort consecutive TB patients treated with new (i.e. bedaquiline, delamanid) repurposed clofazimine, linezolid) drugs, based WHO aDSM project. Adverse were collected prospectively after attribution...
No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate to treat multidrug- extensively drug-resistant tuberculosis (MDR- XDR-TB). The aim this observational was evaluate therapeutic contribution, effectiveness, profile added a background regimen when treating MDR- XDR-TB cases. Patients treated with meropenem/clavulanate-containing (n=96) showed greater drug resistance than those exposed meropenem/clavulanate-sparing (n=168): in former group more...
No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanate versus meropenem/clavulanate treat multidrug- extensively drug-resistant tuberculosis (MDR- XDR-TB). The aim this observational was compare therapeutic contribution added background regimens MDR- XDR-TB cases. 84 patients treated with imipenem/clavulanate-containing showed a similar median number antibiotic resistances (8 8) but more fluoroquinolone resistance (79.0% 48.9%,...
The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. aim study is to prospectively evaluate effectiveness bedaquiline (and/or delamanid)- containing regimens a large cohort consecutive TB patients treated globally. This observational, prospective based on data collected and provided by Global Tuberculosis Network (GTN) centres analysed twice year. All (including children/adolescents) with and/or delamanid...
Over the past decades, prevalence and incidence of non-tuberculous mycobacteria pulmonary disease (NTM-PD) have increased worldwide, with Mycobacterium avium complex being most common causative agents [1–5]. The 2020 ATS/ERS/ESCMID/IDSA guidelines recommended a treatment regimen at least three drugs, including macrolide, in patients nodular-bronchiectatic, macrolide-susceptible (MAC-PD) [6]. For cavitary or advanced/severe bronchiectatic disease, suggest addition parenteral amikacin into...
Identifying patients at risk of nontuberculous mycobacterial pulmonary disease (NTM-PD) is challenging. Delays in NTM-PD identification and management are associated with declining lung function increased morbidity mortality.
Intravenous amikacin, recommended for severe or recurrent
Manufacturing systems are making a shift towards intelligent and predictive Cyber Physical Systems (CPS) with enhanced sensing communication capabilities. Current maintenance activities based on predefined schedules, without considering the working state of equipment thus leading to over-maintained machinery. The cost related production process interruption for dispatching personnel restore proper conditions is high. In this context, study presents an extendable re-usable scheduling approach...
CD4+ cells expressing Interferon-γ (IFN-γ), following stimulation with specific mycobacterial antigens, identified flow cytometry (FCM-CD4+IFN-γ+), is a new method for the diagnosis of Mycobacterium tuberculosis (MTB) infection. The aim this study to investigate performance FCM-CD4+IFN-γ+ in comparison tuberculin skin test (TST) and Quantiferon TB Gold In-Tube (QFT-G-IT) latent MTB infection (LTBI), close contacts patients rheumatic diseases under treatment anti-TNFa other biologic...
The aim was to assess the distribution of nontuberculous mycobacteria (NTM) in treated patients with pulmonary disease (PD) Greece.Patients for NTM PD at two largest chest diseases hospitals Greece, period 1990-2013 were investigated. For years 2005-2013 data on isolation frequency recorded.M. avium complex (MAC) predominant cause followed by M. kansasii and rapid growing (RGM). pathogenicity RGM significantly lower than this MAC kansasii. An increase observed percentage isolated species...
We present the case of a 60-year old female patient, with 10 year history non-CF bronchiectasis and use macrolides as maintenance immunomodulatory treatment, who was diagnosed macrolide-resistant Mycobacterium avium complex lung disease. Macrolides' effect is appealing for non- CF patients, hiding high risk resistance emergence.
Severe Mycolicibacter kumamotonensis-pulmonary disease was diagnosed in a 68-year-old immunocompetent woman Greece; the initially treated as tuberculosis. The patient responded favorably to new treatment regimen of azithromycin, amikacin, moxifloxacin, and linezolid. Complete symptom resolution radiologic improvement resulted.
is a difficult-to-treat, multidrug-resistant human pathogen. Relebactam has been shown to inhibit
We present the first fatal case of extensively drug-resistant tuberculosis (XDR-TB) in an injecting drug user (IDU) Athens, Greece, co-infected with human immunodeficiency virus and hepatitis C discuss implications for public health. Despite immediate initiation treatment, patient's condition gradually deteriorated he died 16 days after hospital admission because multiple organ failure. The contact tracing investigation revealed no further infections among contacts.
1. Moule MG, Cirillo JD. Mycobacterium tuberculosis Dissemination Plays a Critical Role in Pathogenesis. Front Cell Infect Microbiol. 2020;10:65. doi:10.3389/fcimb.2020.00065 CrossRef Google Scholar
<b>Introduction:</b> Treatment of NTM pulmonary disease remains a challenge for the respiratory physician. It is lengthy, while drug adverse effects often lead to treatment discontinuation. Currently, great research taking place towards new and effective development with better safety tolerability profile. Patients methods: We present 11 patients Greek origin (median age 65 years) lung disease, who were treated Amikacin Liposomal Inhalation Suspension (ALIS) between 2020 2022. Nine out...